Key facts
- It has raised $50K; the latest was Early Stage VC ($50K) in Oct 2025.
- PharmassetX has filed 1 Form D with the SEC, most recently Oct 2025 ($50K sold to 1 investors).
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for PharmassetX
- ·The full record, as it builds
Funding rounds
No funding rounds for PharmassetX are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About PharmassetX
Developer of a patent-pending drug designed to treat chronic inflammatory diseases. The company offers targeted therapy for Pouchitis, enabling patients suffering from chronic inflammatory diseases to achieve meaningful relief beyond symptomatic treatment.
- Sector
- Healthcare
- HQ
- Louisville, KY, United States
- Founded
- 2024
- Website
- pharmassetx.com/
- Ownership
- Privately Held (backing)
PharmassetX doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in PharmassetX shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on PharmassetX in its N-PORT filings yet. We sweep new filings monthly.